Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Fennec Pharmaceuticals (FENC) Gains from Sales and Divestitures (2021 - 2022)

Fennec Pharmaceuticals filings provide 2 years of Gains from Sales and Divestitures readings, the most recent being $26000.0 for Q4 2022.

On a quarterly basis, Gains from Sales and Divestitures fell 23.53% to $26000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $26000.0, a 23.53% decrease, with the full-year FY2022 number at $26000.0, down 23.53% from a year prior.
Gains from Sales and Divestitures hit $26000.0 in Q4 2022 for Fennec Pharmaceuticals, down from $34000.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $34000.0 in Q4 2021 to a low of $26000.0 in Q4 2022.